m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05580
 [1]
m6A modification hsa-miR-29a-3p hsa-miR-29a-3p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-29a-3p TNFRSF1A  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-29a-3p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-29a-3p microRNA View Details
Regulated Target Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary The knockout of methyltransferase 3 (N6-adenosine-methyltransferase complex catalytic subunit) removed the m6A modification of hsa-miR-29a-3p and reduced miR-29a-3p expression. These findings suggest that miR-29a-3p is a potential target that can be manipulated for ALI/ARDS. miR-29a-3p targets Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) to inhibit PANoptosis in alveolar epithelial cells
Responsed Disease Acute respiratory distress syndrome ICD-11: CB00
 Disease Info 
Cell Process Panoptosis
In-vitro Model
 A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
In-vivo Model All the mice were randomly divided into three groups: the normal saline group (NS), the lipopolysaccharide + negative control group (LPS + NC), and the LPS + miR-29a-3p agomir group (LPS + Agomir).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) 14 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name VB-111 Phase 3 [2]
MOA Modulator
External Link
TTD: D0S4LV
 Compound Name Drug 2862277 Phase 2 [3]
External Link
TTD: D07LMO
 Compound Name GSK1995057 Phase 1 [4]
External Link
TTD: D08ENB
 Compound Name AVX-470 Phase 1 [5]
Synonyms
Anti-TNF antibody (oral, IBD), Avaxia Biologics
    Click to Show/Hide
External Link
TTD: D03HIG
 Compound Name Anti-IFN gamma Terminated [5]
Synonyms
AGT-1; Anti-IFN gamma (autoimmune diseases); Anti-cytokine antibodies, Advanced Biotherapy; Anti-cytokine therapy, Advanced Biotherapy; Anti-IFN gamma (autoimmune diseases), Advanced Biotherapy
    Click to Show/Hide
External Link
TTD: D0R4OD
 Compound Name TNFR1 NAM Investigative [3]
Synonyms
TNFR1 negative allosteric modulators, Addex
    Click to Show/Hide
MOA Modulator
External Link
TTD: D03IMU
 Compound Name NM-9405 Investigative [3]
Synonyms
Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc
    Click to Show/Hide
External Link
TTD: D08TQK
 Compound Name TNFmab Investigative [5]
Synonyms
TNFmab (rheumatoid arthritis)
    Click to Show/Hide
External Link
TTD: D0B6WV
 Compound Name ADS-0101 Investigative [3]
Synonyms
ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta
    Click to Show/Hide
External Link
TTD: D0G9XS
 Compound Name Recombinant human TNF receptor Investigative [5]
Synonyms
Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0P4WI
 Compound Name TNFcept Investigative [5]
Synonyms
TNFcept (rheumatoid arthritis)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0U4QQ
 Compound Name NM-2014 Investigative [3]
MOA Modulator
External Link
TTD: D0W0BN
 Compound Name ALF-421 Investigative [5]
Synonyms
CORM-A1; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation); Carbon monoxide-releasing molecules (inflammatory diseases), Alfama; Macromolecular carrier-linked CORMs (inflammation), Alfama; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation), Alfama
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0W7FG
 Compound Name Anti-TNF human mabs Investigative [5]
Synonyms
Anti-TNF human mAbs (autoimmune disease); Anti-TNF human mAbs (autoimmune disease), Xencor; Anti-TNF human monoclonal antibodies (autoimmune disease), Xencor
    Click to Show/Hide
External Link
TTD: D0X8SM
CB00: Acute respiratory distress syndrome 18 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Surfactant ta Approved [6]
Synonyms
Surfacten (TN)
    Click to Show/Hide
External Link
TTD: D0P4EC
 Compound Name Picrotoxin Approved [7]
Synonyms
Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2
    Click to Show/Hide
External Link
CID: 31304
TTD: D0KR9U
DrugBank: DB00466
 Compound Name Lucinactant Approved [8]
Synonyms
Surfaxin (TN)
    Click to Show/Hide
External Link
CID: 145722609
TTD: D0F4HB
 Compound Name Colfosceril palmitate Approved [6]
Synonyms
DPPC; Exosurf; Exosurf Neonatal; Exosurf Paedriatic; Surfexo Neonatal; BW-129Y83
    Click to Show/Hide
External Link
CID: 452110
TTD: D0A1XS
DrugBank: DB09114
 Compound Name Poractant alfa Approved [6]
External Link
TTD: D08SCQ
 Compound Name HL-10 Phase 3 [9]
External Link
TTD: D04OGP
 Compound Name BAY1097761 Phase 2 [10]
Synonyms
Adrenomedullin Pegol; PEG-ADM
    Click to Show/Hide
External Link
TTD: DK8BS7
 Compound Name Aerosurf Phase 2 [11]
External Link
TTD: DIAM05
 Compound Name ALT-836 Phase 2 [12]
External Link
TTD: D04DKL
 Compound Name Pneumostem Phase 2 [13]
External Link
TTD: D03YIX
 Compound Name GSK1995057 Phase 1 [14]
External Link
TTD: D08ENB
 Compound Name ALS-886 Terminated [15]
External Link
TTD: D0VS2M
 Compound Name TLC-C-53 Terminated [16]
Synonyms
Ventus; C-53
    Click to Show/Hide
External Link
TTD: D0U4WB
 Compound Name PYC-38 Investigative [17]
Synonyms
Phylomer (acute respiratory distress), Phylogica
    Click to Show/Hide
External Link
TTD: D0G6TX
 Compound Name ED1 Investigative [18]
Synonyms
ethylenediamine scaffold, 10; BDBM31426; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid
    Click to Show/Hide
External Link
CID: 25181318
TTD: D0G1SN
 Compound Name ACS-6 Investigative [17]
Synonyms
H2S-donating sildenafil (ARDS), CTG Pharma
    Click to Show/Hide
External Link
CID: 11549436
TTD: D05JLG
 Compound Name ED45 Investigative [18]
External Link
TTD: D01NJE
 Compound Name DD7 Investigative [18]
External Link
TTD: D00QBV
References
Ref 1 MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis. Aging Dis. 2022 Jun 1;13(3):899-909. doi: 10.14336/AD.2021.1023. eCollection 2022 Jun.
Ref 2 Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 15;19(14):3996-4007. doi: 10.1158/1078-0432.CCR-12-2079. Epub 2013 Apr 15.
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
Ref 4 Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.
Ref 5 Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4051).
Ref 8 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
Ref 9 ClinicalTrials.gov (NCT00742482) Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy. U.S. National Institutes of Health.
Ref 10 ClinicalTrials.gov (NCT04417036) Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial. U.S.National Institutes of Health.
Ref 11 ClinicalTrials.gov (NCT04264156) A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks GA. U.S. National Institutes of Health.
Ref 12 ClinicalTrials.gov (NCT00879606) Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT01897987) Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM Phase-II Clinical Trial. U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT01587807) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057. U.S. National Institutes of Health.
Ref 15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017839)
Ref 16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004234)
Ref 17 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 18 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.